ClinicalTrials.gg
CompletedNCT02174822Updated Feb 18, 2022

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

A Phase 1 interventional study of AVP-786 and Paroxetine in Drug-drug Interaction, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and between AVP-786 and duloxetine.

02

Conditions studied

  • Drug-drug Interaction

Keywords

  • Drug-drug interaction
  • Pharmacokinetics
  • Healthy Volunteers
  • deuterated dextromethorphan
  • deuterated dextromethorphan with quinidine
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and females
  • 18 - 50 years of age
  • 18 - 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History or presence of significant disease
  • History of substance abuse and/or alcohol abuse with the past 3 years
  • Use of tobacco-containing or nicotine-containing products within 6 months
  • Use of any prescription or the over-the-counter medications within 14 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Paroxetine + AVP-786

    Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.

    Drug: AVP-786 · Drug: Paroxetine

  • Experimental
    AVP-786 + paroxetine

    AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20

    Drug: AVP-786 · Drug: Paroxetine

  • Experimental
    Duloxetine + AVP-786

    Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.

    Drug: AVP-786 · Drug: Duloxetine

  • Experimental
    AVP-786 + duloxetine

    AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.

    Drug: AVP-786 · Drug: Duloxetine

Interventions

06

What researchers measure

Primary outcomes

  1. Change in plasma concentrations of paroxetine after combined dosing with AVP-786 paroxetine in healthy subjects

    Time frame: 20 days

  2. Change in plasma concentration of AVP-786 (parent and metabolites) after dosing in combination with paroxetine.

    Time frame: 20 days

  3. Change in plasma concentration of duloxetine after combined dosing with AVP-786

    Time frame: 13 days

  4. Change in plasma concentration of AVP-786 after combined dosing with duloxetine.

    Time frame: 13 days

Secondary outcomes

  1. Incidence of adverse events (AEs) for AVP-786 and paroxetine

    Time frame: 20 days

  2. Incidence of adverse events (AEs) for AVP-786 and duloxetine

    Time frame: 13 days

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Mar 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2014
First posted
Jun 26, 2014
Start
Jan 2014
Primary completionActual
Mar 2014
CompletionActual
Apr 2014
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02174822
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Jan 2014
Primary completion
Mar 2014
Completion
Apr 2014
Last update
Feb 18, 2022

Study contacts

Jason Lickliter, MBBS PhD FRACP
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine · Paroxetine · Duloxetine

Start the discussion